Delivery Order SPE2DB22D2206-SPE2DB26FDV48
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,191.17 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector units on September 23, 2025, with completion scheduled for September 24, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,936.96 delivery order on July 23, 2025, for XYOSTED 75 mg/0.5 mL auto-injector units (0.5 mL). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 24, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a $2,150.75 delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded a $1,436.03 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of June 2, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor specializing in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies, valued at $1,500.30 with an ultimate completion date of October 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under a larger contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with a ceiling value of $1,314.73 under a firm fixed-price arrangement. The contract was competitively awarded without set-aside provisions and is due for completion by September 9, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Xyosted 50 mg/0.5 ml auto-injector pre-filled pens valued at $1,653.41. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 23, 2025. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $3,046.96 to AmerisourceBergen Drug Corp for the supply of Xyosted 50 mg/0.5 ml auto-injector units. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and was executed on June 25, 2025, with an ultimate completion date of June 26, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $1,270.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The delivery...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB26FDV48Delivery Order
The Defense Logistics Agency awarded a $1,303.52 delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector units, with an ultimate completion date of October 31, 2025. This competitively awarded, non-set-aside contract is classified as a firm fixed price delivery order and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of medications, specialty pharmaceuticals, and medical supplies to military healthcare programs and other federal health systems. Xyosted, a testosterone replacement therapy auto-injector, supports the Defense Health Agency's medical supply needs and demonstrates the contractor's capability to fulfill specialized pharmaceutical delivery requirements across therapeutic domains through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 10/30/25 |